Literature DB >> 19421362

Skin autofluorescence is elevated in acute myocardial infarction and is associated with the one-year incidence of major adverse cardiac events.

D J Mulder1, P L van Haelst, R Graaff, R O Gans, F Zijlstra, A J Smit.   

Abstract

BACKGROUND.: ST-elevation myocardial infarction (STEMI) is associated with increased inflammation and oxidative stress, enhancing the formation of advanced glycation endproducts (AGEs). These encompass a characteristic fluorescence pattern, which can be non-invasively measured as skin autofluorescence (AF). In this study we investigate whether skin AF is elevated in STEMI, its association with inflammatory and glycaemic stress and its predictive value for future events. METHODS.: Skin AF was measured in 88 STEMI patients (mean age 64+/-13 years) within 72 hours and around six months after discharge, in 81 stable coronary artery disease (sCAD) patients (64+/-10 years), and in 32 healthy controls (63+/-11 years). The cumulative one-year incidence of all-cause mortality and hospitalisation for myocardial infarction or heart failure was documented. RESULTS.: Skin AF was significantly higher in STEMI compared with sCAD and controls, irrespective of confounders, and was associated with HbA1c and C-reactive protein. Skin AF decreased significantly in STEMI patients, when measured >200 days after discharge. In STEMI patients, skin AF above the median was predictive of future events (hazard ratio 11.6, 95% CI 1.5 to 90.8, p=0.019). CONCLUSION.: Skin AF is elevated in STEMI, is associated with inflammation and glycaemic stress, and predicts future major adverse cardiac events. (Neth Heart J 2009;17:162-8.Neth Heart J 2009;17:162-8.).

Entities:  

Keywords:  advanced glycation endproducts; autofluorescence; inflammation; myocardial infarction; oxidative stress

Year:  2009        PMID: 19421362      PMCID: PMC2669246          DOI: 10.1007/BF03086239

Source DB:  PubMed          Journal:  Neth Heart J        ISSN: 1568-5888            Impact factor:   2.380


  33 in total

1.  Advanced glycation end products in nondiabetic patients with coronary artery disease.

Authors:  M Kanauchi; N Tsujimoto; T Hashimoto
Journal:  Diabetes Care       Date:  2001-09       Impact factor: 19.112

2.  Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts.

Authors:  L Park; K G Raman; K J Lee; Y Lu; L J Ferran; W S Chow; D Stern; A M Schmidt
Journal:  Nat Med       Date:  1998-09       Impact factor: 53.440

3.  Malondialdehyde-modified LDL as a marker of acute coronary syndromes.

Authors:  P Holvoet; D Collen; F Van de Werf
Journal:  JAMA       Date:  1999-05-12       Impact factor: 56.272

4.  High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men: a population-based 18-year follow-up study.

Authors:  Bente K Kilhovd; Auni Juutilainen; Seppo Lehto; Tapani Rönnemaa; Peter A Torjesen; Kåre I Birkeland; Tore J Berg; Kristian F Hanssen; Markku Laakso
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-02-03       Impact factor: 8.311

5.  Simple non-invasive assessment of advanced glycation endproduct accumulation.

Authors:  R Meerwaldt; R Graaff; P H N Oomen; T P Links; J J Jager; N L Alderson; S R Thorpe; J W Baynes; R O B Gans; A J Smit
Journal:  Diabetologia       Date:  2004-07-09       Impact factor: 10.122

Review 6.  Endothelial dysfunction in acute and chronic coronary syndromes: evidence for a pathogenetic role of oxidative stress.

Authors:  Marco Valgimigli; Elisa Merli; Patrizia Malagutti; Olga Soukhomovskaia; Giordano Cicchitelli; Gaetano Macrì; Roberto Ferrari
Journal:  Arch Biochem Biophys       Date:  2003-12-15       Impact factor: 4.013

7.  Skin autofluorescence is elevated in patients with stable coronary artery disease and is associated with serum levels of neopterin and the soluble receptor for advanced glycation end products.

Authors:  Douwe J Mulder; Paul L van Haelst; Sascha Gross; Karina de Leeuw; Johan Bijzet; Reindert Graaff; Rijk O Gans; Felix Zijlstra; Andries J Smit
Journal:  Atherosclerosis       Date:  2007-05-17       Impact factor: 5.162

8.  Skin autofluorescence is elevated in acute myocardial infarction and is associated with the one-year incidence of major adverse cardiac events.

Authors:  D J Mulder; P L van Haelst; R Graaff; R O Gans; F Zijlstra; A J Smit
Journal:  Neth Heart J       Date:  2009-04       Impact factor: 2.380

9.  Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis.

Authors:  Josephine M Forbes; Louis Teo Loon Yee; Vicki Thallas; Markus Lassila; Riccardo Candido; Karin A Jandeleit-Dahm; Merlin C Thomas; Wendy C Burns; Elizabeth K Deemer; Susan R Thorpe; Susan M Thorpe; Mark E Cooper; Terri J Allen
Journal:  Diabetes       Date:  2004-07       Impact factor: 9.461

10.  Urinary 8-iso-prostaglandin F2alpha as a risk marker in patients with coronary heart disease: a matched case-control study.

Authors:  Edzard Schwedhelm; Asja Bartling; Henrike Lenzen; Dimitrios Tsikas; Renke Maas; Jens Brümmer; Frank-Mathias Gutzki; Jürgen Berger; Jürgen C Frölich; Rainer H Böger
Journal:  Circulation       Date:  2004-02-02       Impact factor: 29.690

View more
  27 in total

Review 1.  Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms.

Authors:  Alin Stirban; Thomas Gawlowski; Michael Roden
Journal:  Mol Metab       Date:  2013-12-07       Impact factor: 7.422

2.  Plasma Levels of Advanced Glycation End Products Are Related to the Clinical Presentation and Angiographic Severity of Symptomatic Lower Extremity Peripheral Arterial Disease.

Authors:  Anand Prasad; James R Lane; Sotirios Tsimikas; Ehtisham Mahmud; Srikrishna Khandrika; Peter Bekker; Manjusha Ilapakurti; Dan Nguyen; Amir Ravandi; Travis Israel
Journal:  Int J Angiol       Date:  2015-03-23

3.  Consequences of Advanced Glycation End Products Accumulation in Chronic Kidney Disease and Clinical Usefulness of Their Assessment Using a Non-invasive Technique - Skin Autofluorescence.

Authors:  Mihaela Oleniuc; Irina Secara; Mihai Onofriescu; Simona Hogas; Luminita Voroneanu; Dimitrie Siriopol; Adrian Covic
Journal:  Maedica (Buchar)       Date:  2011-10

Review 4.  Skin Autofluorescence - A Non-invasive Measurement for Assessing Cardiovascular Risk and Risk of Diabetes.

Authors:  Alin Stirban; Lutz Heinemann
Journal:  Eur Endocrinol       Date:  2014-08-28

5.  Traditional and emerging indicators of cardiovascular risk in chronic obstructive pulmonary disease.

Authors:  Michelle John; Tricia M McKeever; Maath Al Haddad; Ian P Hall; Ian Sayers; John R Cockcroft; Charlotte E Bolton
Journal:  Chron Respir Dis       Date:  2016-03-10       Impact factor: 2.444

6.  RAGE influences obesity in mice. Effects of the presence of RAGE on weight gain, AGE accumulation, and insulin levels in mice on a high fat diet.

Authors:  B Leuner; M Max; K Thamm; C Kausler; Y Yakobus; A Bierhaus; S Sel; B Hofmann; R-E Silber; A Simm; N Nass
Journal:  Z Gerontol Geriatr       Date:  2012-02       Impact factor: 1.281

Review 7.  Dicarbonyl Stress in Diabetic Vascular Disease.

Authors:  Bernd Stratmann
Journal:  Int J Mol Sci       Date:  2022-05-31       Impact factor: 6.208

8.  Skin autofluorescence is elevated in acute myocardial infarction and is associated with the one-year incidence of major adverse cardiac events.

Authors:  D J Mulder; P L van Haelst; R Graaff; R O Gans; F Zijlstra; A J Smit
Journal:  Neth Heart J       Date:  2009-04       Impact factor: 2.380

9.  Skin autofluorescence based decision tree in detection of impaired glucose tolerance and diabetes.

Authors:  Andries J Smit; Jitske M Smit; Gijs J Botterblom; Douwe J Mulder
Journal:  PLoS One       Date:  2013-06-04       Impact factor: 3.240

10.  Skin intrinsic fluorescence is associated with coronary artery disease in individuals with long duration of type 1 diabetes.

Authors:  Baqiyyah N Conway; Vanita R Aroda; John D Maynard; Nathaniel Matter; Stephen Fernandez; Robert E Ratner; Trevor J Orchard
Journal:  Diabetes Care       Date:  2012-07-30       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.